In real-world patients with mHSPC, a PSA cutoff of 0.2 ng/mL after 6 to 12 months of intensified hormone therapy predicts survival outcomes. An absolute PSA level of 0.2 ng/mL or more at 6 to 12 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果